Liraglutide 3.0 Mg Improves Body Weight and Cardiometabolic Risk Factors in Overweight or Obese Adults without Diabetes: The Scale Obesity and Prediabetes Randomized, Double-Blind, Placebo-Controlled 56-Week Trial

被引：0
|
作者：
Le Roux, Carel [1 ]
Astrup, Arne [2 ]
Fujioka, Ken [3 ]
Greenway, Frank Lyons [4 ]
Halpern, Alfredo [5 ]
Krempf, Michel [6 ]
Lau, David C. [7 ]
Ortiz, Rafael Violante [8 ]
Wilding, John [9 ]
Jensen, Christine Bjorn [10 ]
Pi-Sunyer, F. Xavier [11 ]
机构：
[1] Univ Coll Dublin, Dublin, Ireland
[2] Univ Copenhagen, Frederiksberg C, Denmark
[3] Scripps Clin, La Jolla, CA 92037 USA
[4] Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA
[5] Univ Sao Paulo, Sao Paulo, Brazil
[6] Hop Nord Laennec, Nantes, France
[7] Univ Calgary, Calgary, AB, Canada
[8] Inst Mexicano Seguro Social, Cuidad Madero, Tamaulipas, Mexico
[9] Univ Liverpool, Liverpool, Merseyside, England
[10] Novo Nordisk AS, Soborg, Norway
[11] St Lukes Roosevelt Hosp, New York, NY 10025 USA
来源：
ENDOCRINE REVIEWS | 2014年 / 35卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT-0937
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Safety and Tolerability of Liraglutide 3.0 Mg in Overweight and Obese Adults: The Scale Obesity and Prediabetes Randomized, Double-Blind, Placebo-Controlled 56-Week Trial
    Lau, David C.
    Astrup, Arne
    Fujioka, Ken
    Greenway, Frank Lyons
    Halpern, Alfredo
    Krempf, Michel
    Le Roux, Carel
    Ortiz, Rafael Violante
    Wilding, John
    Jensen, Christine Bjorn
    Pi-Sunyer, F. Xavier
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [2] Liraglutide 3.0 Mg Improves Insulin Secretion and Action in Overweight and Obese Adults without Diabetes: Results from Scale Obesity and Prediabetes, a Randomized, Double-Blind and Placebo-Controlled 56-Week Trial
    Wilding, John
    Astrup, Arne
    Fujioka, Ken
    Greenway, Frank Lyons
    Halpern, Alfredo
    Krempf, Michel
    Lau, David C.
    Le Roux, Carel
    Ortiz, Rafael Violante
    Overgaard, Rune Viig
    Jensen, Christine Bjorn
    Pi-Sunyer, F. Xavier
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [3] Liraglutide 3.0 mg for weight management in obese/overweight adults with type 2 diabetes: SCALE diabetes 56-week randomised, double-blind, placebo-controlled trial
    Davies, M. J.
    Bergenstal, R.
    Bode, B.
    Kushner, R.
    Lewin, A.
    Skjoth, T. V.
    Jensen, C. B.
    DeFronzo, R.
    DIABETOLOGIA, 2014, 57 : S22 - S23
  • [4] Liraglutide 3.0 mg for Weight Management in Obese/Overweight Adults with Type 2 Diabetes: Results from the SCALE™ Diabetes 56-Week Randomized, Double-Blind, Placebo-Controlled Trial
    Davies, Melanie
    Bode, Bruce W.
    Kushner, Robert F.
    Lewin, Andrew J.
    Skjoth, Trine V.
    Jensen, Christine B.
    Defronzo, Ralph A.
    DIABETES, 2014, 63 : A26 - A26
  • [5] Liraglutide 3.0 Mg Reduces the Prevalence of Prediabetes and Delays Onset of Type 2 Diabetes in Overweight and Obese Adults: Results from Scale Obesity and Prediabetes, a Randomized, Double-Blind and Placebo-Controlled 56-Week Trial
    Pi-Sunyer, F. Xavier
    Astrup, Arne
    Fujioka, Ken
    Greenway, Frank Lyons
    Halpern, Alfredo
    Krempf, Michel
    Lau, David C.
    Le Roux, Carel
    Ortiz, Rafael Violante
    Jensen, Christine Bjorn
    Wilding, John
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [6] Effect of liraglutide 3.0/1.8 mg on body weight and cardiometabolic risk factors in overweight/obese adults with type 2 diabetes: SCALE diabetes randomised, double-blind, 56-week trial
    Bode, B.
    DeFronzo, R.
    Bergenstal, R.
    Kushner, R.
    Lewin, A.
    Skjoth, T. V.
    Jensen, C. B.
    Davies, M.
    DIABETOLOGIA, 2014, 57 : S83 - S83
  • [7] Effects of Liraglutide 3.0 Mg and 1.8 Mg on Body Weight and Cardiometabolic Risk Factors in Overweight and Obese Adults with Type 2 Diabetes Mellitus (T2DM): The Scale Diabetes Randomized, Double-Blind, Placebo-Controlled, 56-Week Trial
    DeFronzo, Ralph Anthony
    Bergenstal, Richard Maurit
    Bode, Bruce
    Kushner, Robert
    Lewin, Andrew J.
    Skjoth, Trine Vang
    Jensen, Christine Bjorn
    Davies, Melanie
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [8] Efficacy and safety of liraglutide 3.0 mg in adult overweight and obese weight loss responders without diabetes: results of the randomised, double-blind, placebo-controlled 56 week SCALE Obesity and Prediabetes trial
    Bain, S. C.
    O'Neil, P.
    Fujioka, K.
    Ortiz, R. Violante
    Jensen, C. B.
    Nzeakor, N.
    Astrup, A.
    DIABETIC MEDICINE, 2016, 33 : 64 - 64
  • [9] Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial
    Krempf, M.
    Astrup, A.
    le Roux, C.
    Fujioka, K.
    Greenway, F.
    Halpern, A.
    Lau, D. C. W.
    Violante Ortiz, R.
    Wilding, J. P. H.
    Jensen, C. B.
    Lillleore, S. K.
    Pi-Sunyer, X.
    DIABETOLOGIA, 2014, 57 : S368 - S368
  • [10] Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors: SCALE obesity and prediabetes randomised, double-blind, placebo-controlled 3-year trial
    le Roux, C. W.
    Astup, A.
    Greenway, F.
    Krempf, M.
    Vettor, R.
    Manning, L. Shapiro
    Lilleore, S. K.
    Fujioka, K.
    DIABETOLOGIA, 2016, 59 : S329 - S329
12345